P
rion diseases or transmissible spongiform encephalopathies are lethal neurodegenerative disorders affecting many animal species. They include bovine spongiform encephalopathy of cattle, chronic wasting disease of deer and elk, and CreutzfeldtJakob disease in humans. The causative agent is termed prion (1) and was proposed to be identical with PrP Sc , a pathological conformer of the cellular prion protein (PrP C ) encoded by the Prnp gene (2) . PrP C is expressed on the surface of almost all cells in the body, but at particularly high levels on neurons in the peripheral and central nervous systems. PrP C is essential for the development of prion disease, and Prnp o/o mice, which lack PrP C , are resistant to scrapie (3) .
Bovine spongiform encephalopathy (BSE) (4) is caused by prions amplified through the bovine food chain (5) . Transmission of bovine prions to humans has given rise to variant Creutzfeldt-Jakob disease (vCJD) (6) . Although the incidence of BSE and vCJD may be stabilizing or even declining, the steep rise of chronic wasting disease (7) underlines the fact that prion diseases of farm and wild animals still represent a major threat. Thus, there is an urgent and growing need for efficient prophylactic and͞or therapeutic measures against prion diseases (8) .
Although prions use immune and lymphoreticular cells to gain access to the brain (9) , several reports indicate that humoral immune responses to the PrP can antagonize prion infection. This is true even when such responses are directed primarily against PrP C and do not selectively target PrP Sc . mAbs and F(ab) fragments recognizing PrP were shown to prevent de novo scrapie infection and to abolish PrP Sc as well as prion infectivity in chronically scrapie-infected neuroblastoma cells (10) . Further, transgenic expression of anti-PrP antibodies in mice arrested peripheral scrapie pathogenesis (11) . In line with our results, White and colleagues (12) confirmed the efficiency of anti-PrP antibodies in preventing prion disease by injecting such antibodies into WT mice upon peripheral prion challenge.
The prionostatic efficacy of anti-PrP antibodies is highest in extraneural compartments: transgenic 6H4 mice expressing anti-PrP-specific IgM molecules were not protected when prions were administered intracerebrally (F.L.H. and A.A., unpublished observations), and passive transfer of PrP-specific IgGs (12) was inefficient when started after onset of clinical signs. This finding may be caused by the limited influx of Igs into the CNS and the high prion load of clinically symptomatic animals. By providing stable, sustained titers, active immunization may obviate to some of the problems listed above. However, host tolerance to endogenous PrP C remains a major obstacle to devising active immunization regimens. Nevertheless, several recent studies suggest that the induction of anti-PrP antibodies in WT mice is in principle feasible (13) (14) (15) (16) (17) (18) . Although anti-PrP Ig titers could be measured in most of these studies, the titers were rather low. Accordingly, the biological efficacy of these immunization series, if evaluated at all, was limited, emphasizing the need for alternative strategies.
The current study explores the efficacy of active immunization strategies against PrP. We found that none of these strategies leads to antibody titers to native cell-bound PrP C as displayed on the cell surface of PrP C -overexpressing tg33 splenocytes (19) . This finding suggests that host tolerance to endogenous PrP C is nonpermissive to generating high-affinity anti-PrP B cell clones or leads to deletion or anergy of the cognate T cell clones. To gain further insight into the mechanism of tolerance to PrP, a key to defining successful immunization strategies against prions in the future, we investigated the immune responses of transgenic mice exhibiting expression of PrP found that humoral immune responses were not protective if their affinity was restricted to PrP REC . Recombinant Proteins. Generation of recombinant PrP-PrP polyprotein has been described (23) . PrP-PrP consists of a tandem duplication of amino acids 23-231 of the murine PrP lacking the N-and C-terminal signal peptides (amino acids 1-22 and 232-254, respectively). The PrP-PrP protein includes an N-terminal polyhistidine tag that allows purification using a Ni 2ϩ column (23) . Recombinant monomeric murine PrP (PrP REC ) was produced as described (24) . Macrophage inhibitory factor used as an ELISA control was expressed in bacteria by using a similar method.
Methods
Immunization. For the initial injection, 100 g of recombinant PrP-PrP polyprotein or PrP REC was emulsified in complete Freund's adjuvant (CFA) and injected s.c. The same amount of protein emulsified in incomplete Freund's adjuvant (IFA) was used i.p. for boosting injections. Anti-OX40 antibody (100 g per injection) was injected i.p. three times after the first injection and the first two boosts. The immunization protocol is shown in Fig.  1A . Serum samples were collected 14 days after each injection.
Prion Inoculation. Mice were inoculated i.p. with 100 l of brain homogenate containing 10 3 LD 50 infectious units of Rocky Mountain Laboratory strain (passage 5.0) scrapie prions prepared as described (9) .
Anti-PrP REC Antibody Titer. ELISA to detect PrP REC -specific antibodies was performed as described (11) . Briefly, plates were coated with 5 g͞ml recombinant mouse PrP, washed with PBS containing 0.1% (vol͞vol) Tween 20 (PBST), and blocked with 5% BSA. After washing, plates were incubated with 30 l of 2-fold serially diluted serum (1:20 prediluted) in PBST containing 1% BSA and then probed with horseradish peroxidaseconjugated rabbit anti-mouse (IgGϩAϩM, HϩL, or IgG 1:1,000 dilution, Zymed). Plates were developed with 2.2Ј-azino-diethyl-benzothiazolinsulfonate, and optical density was measured at 405 nm. Titer was defined as the highest dilution showing an OD more than two times the technical background, which was calculated as the average of uncoated wells and wells incubated omitting serum.
Anti-Native PrP C Antibody Titer. Splenocytes or blood cells derived from transgenic tg33 mice overexpressing PrP C on T cells (19) were incubated with serum derived from PrP-PrP-or PrP RECimmunized mice or with monoclonal anti-PrP antibody ICSM 18 (a kind gift of John Collinge, University College, London) as described (11 mouse, and (iv) serum of an immunized Prnp ϩ/ϩ mouse and subsequently, with horseradish peroxidase-conjugated rabbit antimouse IgG antibody (Zymed). All sera were diluted 1:100 in blocking buffer. For detection of PrP Sc , brain homogenates of prion-inoculated mice were prepared in PBS, 0.05% sodium deoxycholate, and 0.05% Nonidet P-40. One part of each homogenate was removed and digested with proteinase K (25 g͞ml) to digest PrP C . Samples corresponding to 40 g of total proteins (Ϫ͞ϩ proteinase K digestion) were loaded on an SDS͞PAGE and transferred onto a nitrocellulose membrane incubated with monoclonal anti-PrP antibody POM-1 (M.P., Martin Vey, and A.A., unpublished data) and horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG 1 antibody (Zymed). Blots were finally incubated with HRP substrate (ECL, Pierce) and exposed on photosensitive film (Kodak).
Recall Assay͞Carboxyfluorescein (CFSE) Staining. Mice were immunized with PrP REC or keyhole limpet hemocyanin (KLH; Sigma) by s.c. injection of 200 g of the respective protein emulsified in CFA. Seven days later, draining lymph nodes (inguinal and axillary) were isolated and homogenized to a single cell suspension. To perform proliferation recall assays, cells were plated in a 96-well plate at a density of 2 ϫ 10 5 cells per well, which had been coated with KLH or PrP REC , respectively, at a concentration of 50 g͞ml before seeding cells. Twenty four hours later, 5 Ci͞ml radioactive [ 3 H]thymidine was added. Twenty four hours later, cells were harvested, and radioactivity was measured with a ␤-counter system (1450 MicroBeta, PerkinElmer). CFSE staining was accomplished by adding CFSE at a final concentration of 10 M to lymph node cells that had been adjusted to 1.5 cells ϫ 10 7 ͞ml. Cells were incubated with CFSE for 10 min at room temperature, avoiding bright light, washed once, and, thereafter, cultured in 6-well plates (4 ϫ 10 6 per well) in the presence or absence of KLH or PrP REC , respectively at a concentration of 50 g͞ml. Four days later, cells were stained with allophycocyanin (APC)-labeled anti-B220 (B cells), APClabeled anti-CD4 (T helper cells), or APC-labeled anti-CD8 (cytotoxic T cells) antibodies after one further washing step, and FACS analysis was performed, as described above. All antibodies were obtained from Becton Dickinson.
Isolation of Total RNA and Quantitative Real-Time RT-PCR. Thymi of sex-matched 6-to 8-week-old mice were dissected, immediately frozen in liquid nitrogen, and stored at Ϫ80°C until further use. Total RNA was isolated by using a variable speed polytron homogenizer and Trizol (Invitrogen) according to the manufacturer's instructions and stored as an ethanolic precipitate at Ϫ20°C. Approximately 20 g of total RNA was processed for removal of contaminating genomic DNA (DNA-Free, Ambion, Austin, TX). First-strand cDNA was synthesized by using 5 g of DNase-treated RNA and NotI-oligo(dT) as primer in a 15-l reaction volume according to the manufacturer's instructions (Amersham Pharmacia Biotech). In parallel, identical reactions were prepared omitting the reverse transcriptase mix to allow validation of complete removal of potentially contaminating genomic DNA (␤-actin PCR, 40 cycles).
Assuming a 1:1 RNA͞cDNA conversion, 33.3 ng of firststrand cDNA was used as template in real-time quantitative PCR measurement of PrP RNA expression levels (Applied Biosystems ABI Prism Sequence Detection System 7700) using SybrGreen technology (PerkinElmer). Three mice of each genotype were analyzed; each sample was measured in triplicate. PrP expression levels were normalized to ␤-actin values and expressed as arbitrary values. All transgenic mice were on the Zrch I Prnp o/o background (25) , which express a PrP-neomycin fusion transcript. Thus, the following primers were designed to allow exclusive measurement of transgenic PrP RNA levels: Prnp-F, 5Ј-gctggccctctttgtgacta-3Ј; Prnp-R, 5Ј-ctgggcttgttccactgatt-3Ј; actin-F, 5Ј-gacggccaggtcatcactat-3Ј; and actin-R, 5Ј-acatctgctggaaggtggac-3Ј. 
Results
We used several immunization strategies to overcome tolerance to PrP C . In a first set of experiments, mice were immunized with bacterially expressed recombinant full-length PrP (PrP REC ) emulsified in CFA and IFA, respectively in combination with anti-OX40 antibody (anti-CD134). This is an agonistic antibody against the signaling molecule CD134, which recently has been shown to break T cell tolerance (26) . However, in contrast to other reports (14) , immunization using PrP REC in CFA͞IFA did not result in measurable anti-PrP REC titers in WT mice in our hands as assessed by ELISA. Additional administration of anti-OX40 antibodies resulted in an insignificant increase of Ab titers (data not shown).
A further immunization approach used a recombinant PrPPrP polyprotein emulsified in CFA͞IFA in combination with anti-OX40 antibodies (Fig. 1 A) , which had been previously shown to elicit antibody responses in WT mice that cured scrapie-infected neuroblastoma cells in vitro (23) . Upon PrPPrP͞CFA immunization, WT mice displayed anti-PrP REC titers as assessed by ELISA (Fig. 1B) and Western blot (Fig. 1D ). Titers were considerably lower than those of PrP-PrP͞CFA-immunized Prnp o/o mice and were not augmented by anti-OX40 (Fig. 1B) . Usage of an irrelevant Escherichia coli-derived protein as ELISA substrate confirmed the specificity to PrP REC of the respective sera (Fig. 1C) .
To determine whether antibodies recognized native PrP C , sera were added to splenocytes of tg33 mice, which transgenically overexpress PrP C on T cells (19) . Binding of serum Ig to native PrP C was assessed by FACS as described (11) . Whereas sera of PrP-PrP͞CFA-immunized Prnp o/o mice strongly stained tg33 splenocytes, none of the WT sera contained antibodies recognizing native PrP C regardless of the immunization method or time point of analysis (Fig. 1G) .
To determine whether the anti-PrP Abs produced upon immunization were of any therapeutic value, we challenged PrP-PrP͞CFA-immunized WT mice with scrapie prions by i.p. injection of the Rocky Mountain Laboratory strain. Despite the presence of substantial anti-PrP REC titers, immunized WT mice did not exhibit significant delays in the onset of prion disease (Fig. 1E) , except for two of eight PrP-PrP͞CFA-immunized WT mice that did not develop scrapie and, accordingly, did not display measurable cerebral PrP Sc at 585 days postinoculation (Fig. 1F) . This finding suggests that antibodies to PrP REC can be induced in WT mice, yet these antibodies do not recognize native PrP, do not interfere with scrapie pathogenesis, and may not be of therapeutic value.
To test the latter hypothesis, we asked whether those anti-PrP antibodies that were previously shown to interfere with prion disease would recognize native PrP C on the surface of tg33 T cells. We found that sera from 6H4 transgenic mice (carrying the (Fig. 2) . In addition, mAb ICSM18, which was shown to exert anti-prion activity in vivo (12) , reacted strongly with tg33 T cells (Fig. 1G) . These results add strength to the conjecture that binding to native PrP C is crucial for anti-prion protection.
The above results point toward host tolerance as a crucial barrier to the induction of functional anti-PrP immune responses. To understand the cellular requirements of tolerance to PrP C , we investigated whether the tissue-specific distribution of PrP determines the outcome of anti-PrP immunization. (22) .
Whereas PrP REC immunization of MBP-PrP mice mounted significant anti-PrP REC antibody titers, NSE-PrP and Alb-PrP mice were unresponsive to immunizations similarly to WT mice (Fig.  3A) . Further analysis revealed that anti-PrP antibodies of immunized MBP-PrP mice consistently recognized native PrP C displayed on tg33 T cells 28 days after immunization ( Fig. 3B and Table 1 ). In contrast, none of five PrP REC ͞CFA-immunized WT mice, and surprisingly also none of five NSE-PrP and five Alb-PrP mice developed detectable anti-PrP C antibodies. Anti-PrP titers in PrP REC -immunized MBP-PrP mice displayed delayed kinetics and were reduced compared to Prnp o/o mice, suggesting that some tolerogenic mechanisms were still operative.
To better understand these surprising differences in the immune response of MBP-PrP, NSE-PrP, Alb-PrP, and control mice upon PrP REC ͞CFA immunization, a recall assay was performed. Lymph node cells of PrP REC ͞CFA-immunized transgenic and control mice were rechallenged with PrP REC in vitro, and the proliferative capacity of T and B cells was assessed. Whereas Prnp o/o lymphocytes exhibited vigorous proliferation, lymphocytes of WT, AlbPrP, and NSE-PrP mice did not proliferate, in agreement with their inability to mount anti-PrP C titers in vivo. Instead, MBP-PrP mice displayed moderate lymphocyte proliferation (Fig. 4A ). These differences were fully attributable to PrP REC -specific responses, because a control antigen used in the same experiment (KLH) induced similar lymphocyte proliferation in all investigated mice (data not shown).
Next, CFSE-labeled B220 ϩ B cell, CD4 ϩ T helper, and CD8 ϩ cytotoxic T cell subsets were analyzed individually for their proliferative capacity upon re-encountering PrP REC . B and CD4 ϩ T helper lymphocyte subsets derived from MBP-PrP mice displayed proliferative responses comparable to Prnp o/o lymphocytes, whereas CD8 ϩ cytotoxic T cells were only moderately proliferative (Fig. 4 B and C) . In contrast, Prnp ϩ/ϩ lymphocytes showed poor or no proliferative responses of B220 ϩ B cells and CD8 ϩ cytotoxic T cells. Prnp
T helper cells were consistently nonresponsive (Fig. 4 B and C) . The fact that few B220 ϩ B cell displayed some proliferative capacity might ac- (Fig. 3B and Table 1 ) most likely because of the lack of T helper support. Thus, tolerance to PrP C in WT mice appears to be mainly caused by an inadequate T helper cell activation, as proposed (27) .
To better understand why T helper cells of WT, NSE-PrP, Alb-PrP, and, in part, MBP-PrP are tolerized to PrP C , we investigated the level of thymic PrP C expression. Expression of antigens within the thymus induces negative selection, i.e., deletion of self-reactive cells during T cell development, a process known as central tolerance. PrP C protein was undetectable in the thymus of Alb-PrP and MBP-PrP mice (data not shown). Prnp mRNA was detected by real-time RT-PCR in WT and all transgenic lines, but mRNA levels were found to be 62-fold lower in Alb-PrP mice, 17-fold lower in MBP-PrP mice, and 3.2-fold lower in NSE-PrP mice than in WT mice (Fig. 5) . Hence the levels of thymic PrP expression did not correlate with the capability to mount anti-PrP C responses, suggesting that tolerance to PrP C is primarily controlled extrathymically and is only marginally affected by PrP C expression in myelinating cells.
Discussion
The original goal of this study was to assess the efficacy of PrP C vaccination as an anti-prion strategy. Disappointingly, active immunization of WT mice with various forms of bacterially expressed recombinant PrP, even in the presence of a variety of adjuvants, did not significantly interfere with prion disease despite the generation of vigorous humoral immune responses to bacterially expressed PrP REC . This result is in stark contrast to the encouraging results obtained by transgenetic B cell reprogramming (11) and passive transfer (12) of anti-PrP C antibodies. We then attempted to elucidate the characteristics discriminating protective vs. nonprotective immune responses. We reasoned that a likely minimal prerequisite might be that protective antibodies recognize the native eukaryotic form of PrP C as expressed on the surface of cells. This hypothesis was analyzed by establishing an assay in which transgenic tg33 T cells, which overexpress PrP C under transcriptional control of the lck promoter, were exposed to sera of immunized mice. Binding was then assessed by quantitative cytofluorimetric analysis. Using this assay, we found that sera of PrP mice as well as sera from 6H4 transgenic mice (Fig. 2 ) and mAb ICSM18 (Fig. 1G) , which was shown to exert anti-prion activity in vivo (12) , reacted strongly with tg33 T cells. Therefore, the presence of anti-native PrP C titers appears to correlate with the capability to interfere with prion pathogenesis, and anti-native PrP C antibodies may represent an indispensable precondition for preventing prion diseases. These findings may explain the very modest effects of active PrP immunization attempts on prion pathogenesis that have been reported by others (14) and should lead to a critical reassessment of the value of immunization protocols, leading to immune responses whose affinity to native PrP C has not been investigated (13) (14) (15) (16) (17) (18) 28) .
What might be the molecular difference between antibodies that only react to PrP REC and those that recognize PrP C ? Because bacterially expressed PrP lacks all glycosylation, the differences may impinge on immunoreactivity to glycomoieties linked to PrP C . However, this cannot fully account for the discrimination between the two forms of PrP, as both the ICSM18 mAb and serum from 6H4 transgenic mice recognize the 19-21 core fragment of PrP Sc , which is devoid of sugar residues. Nor can discrimination be explained by the weaker anti-PrP titers of PrP C -expressing mice, as Prnp o/o sera clearly react with tg33 splenocytes even at dilutions yielding ELISA signals similar to those of Prnp ϩ/ϩ mice (data not shown).
Instead, Prnp o/o mice may develop low-affinity antibodies to PrP C . Although such antibodies may bind to surface-immobilized, arrayed PrP REC , where pure protein is concentrated in a very small area, they may not show reactivity on a more ''demanding'' cell surface microenvironment, where the target protein is present at lower density. Alternatively, PrP C and PrP REC may differ in some structural feature, a contention for which no physical evidence is available, or the microenvironment of PrP C with its associated proteins and lipids masks͞distorts epitopes that are exposed in PrP REC . Logically, such ''pseudoautoimmune'' responses to epitopes that are nonexistent in vivo would be of little anti-prion benefit. Antibodies that recognize both PrP C and PrP REC appear to be more useful, at least in the case of ICSM18 and 6H4; yet our attempts at such immune responses in WT mice were thwarted by their strict tolerance to PrP C .
It follows from the above that understanding the tolerogenic mechanisms preventing the generation of anti-native PrP is overexpressed at vastly supraphysiological levels (11) . Tolerance to PrP C appeared to be tightly regulated and could not be overcome by the administration of stimulatory anti-CD134 antibodies, which were shown to break existing T cell tolerance in another model (26) . Whereas two of eight anti-CD134-treated, PrP polyprotein-immunized mice did not develop scrapie upon prion inoculation, the remaining six CD134-treated mice did not show a significant delay in the onset of prion disease. While far from spectacular, these results suggest that the combination of specific immunogens with CD134 stimulation might marginally influence prion pathogenesis.
Because T helper cell assistance is crucial for mediating adequate B cell responses, unresponsiveness or deletion of the appropriate CD4 Expression of PrP C on B and T lymphocytes was obviously expected to be tolerogenic, similar to what had been found in the hen-egg lysozyme transgenic model (29) . Less surprising, minute PrP C expression levels in any extracerebral nonimmune compartment but myelinating cells prevented humoral anti-PrP C immunity as well. To improve our understanding of the above phenomena, we determined the thymic transcription levels of Prnp in all PrP transgenic mice. Thymic PrP expression did not appear to correlate well with the extent of tolerance, as MBP-PrP thymi yielded stronger signals than Alb-PrP thymi.
Persistent self-antigen in extrathymic compartments can also induce tolerance, and this is one of the mechanisms by which peripheral tolerance is mediated. A compartment that has been shown to be very efficient in conferring peripheral tolerance is the liver (30) , which is in line with the complete lack of anti-PrP C responses in PrP-immunized Alb-PrP mice despite minimal thymic PrP transcription. Although it is widely held that expression of tissue-specific antigens (TSAs) is excluded from the thymus, thus precluding central tolerance, a recent report demonstrates that few medullary epithelial cells within the thymus express TSAs (31), a process that is genetically controlled by the AIRE gene (32) .
Although the development of anti-PrP antibodies recognizing native PrP C in immunized MBP-PrP mice is encouraging, the prionostatic potential of such antibodies cannot be tested directly because oligodendrocytes are intrinsically resistant to prion infection (22) . As B cells transgenically expressing an anti-PrP chain (6H4) in the presence of PrP (33) . This may theoretically represent a serious caveat to PrP immunization approaches. However, none of the anti-PrP mAbs used in that study had been shown to be prionostatic in vivo, and anti-PrP antibodies were neurotoxic only at intracerebral concentrations that would be unlikely to be reached by means of active immunization. Therefore, it would appear premature to halt development of antibody-based anti-prion strategies.
Disappointingly, active PrP immunization of WT mice with bacterially expressed PrP moieties, such as PrP REC and PrP-PrP polyprotein, in the presence of various adjuvants did not suffice to effectively interfere with prion disease. Although WT mice upon PrP immunization mounted anti-PrP antibodies, which bound to recombinant PrP, the native form of PrP C was not recognized. Along with the successful outcome of adoptive antibody transfer experiments and antibody transgenesis, these results suggest that effective anti-prion immunity may necessitate anti-native PrP C titers. The difficulties involved in eliciting development of such anti-PrP C immune responses may reside, at least in part, in peripheral T helper tolerance. Thorough elucidation of the basic mechanisms of such tolerance will be needed to successfully and safely implement active vaccination as a viable anti-prion regimen.
